[go: up one dir, main page]

WO2008001379A3 - Activated myeloid cells for promoting tissue repair and detecting damaged tissue - Google Patents

Activated myeloid cells for promoting tissue repair and detecting damaged tissue Download PDF

Info

Publication number
WO2008001379A3
WO2008001379A3 PCT/IL2007/000797 IL2007000797W WO2008001379A3 WO 2008001379 A3 WO2008001379 A3 WO 2008001379A3 IL 2007000797 W IL2007000797 W IL 2007000797W WO 2008001379 A3 WO2008001379 A3 WO 2008001379A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid cells
tissue
promoting
detecting damaged
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2007/000797
Other languages
French (fr)
Other versions
WO2008001379A2 (en
Inventor
Michal Eisenbach-Schwartz
Oleg Butovsky
Gilad Kunis
Shay Bukshpan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to EP07766828A priority Critical patent/EP2043666A2/en
Publication of WO2008001379A2 publication Critical patent/WO2008001379A2/en
Priority to IL196172A priority patent/IL196172A0/en
Anticipated expiration legal-status Critical
Publication of WO2008001379A3 publication Critical patent/WO2008001379A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A cellular preparation comprising CD11c+ bone marrow-derived myeloid cells is provided for promoting repair of damaged body tissue. When labeled with a suitable imaging agent, the cells can be used to detect and localize a damaged body tissue. The cells are obtained by activation of bone marrow-derived myeloid cells with a cytokine, preferably IL-4.
PCT/IL2007/000797 2006-06-28 2007-06-28 Activated myeloid cells for promoting tissue repair and detecting damaged tissue Ceased WO2008001379A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07766828A EP2043666A2 (en) 2006-06-28 2007-06-28 Activated myeloid cells for promoting tissue repair and detecting damaged tissue
IL196172A IL196172A0 (en) 2006-06-28 2008-12-25 Activated myeloid cells for promoting tissue repair and detecting damaged tissue

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80605506P 2006-06-28 2006-06-28
US60/806,055 2006-06-28
US80726406P 2006-07-13 2006-07-13
US60/807,264 2006-07-13

Publications (2)

Publication Number Publication Date
WO2008001379A2 WO2008001379A2 (en) 2008-01-03
WO2008001379A3 true WO2008001379A3 (en) 2009-04-30

Family

ID=38846103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/000797 Ceased WO2008001379A2 (en) 2006-06-28 2007-06-28 Activated myeloid cells for promoting tissue repair and detecting damaged tissue

Country Status (2)

Country Link
EP (1) EP2043666A2 (en)
WO (1) WO2008001379A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107988157A (en) * 2017-11-28 2018-05-04 航天中心医院 A kind of Dendritic Cells Induced culture medium and its application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678250B (en) 2007-03-02 2013-04-24 史密夫及内修公开有限公司 Device and method for filter cleaning by ultrasound, backwashing and filter movement in biological sample filtration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUTOVSKY ET AL.: "Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and reders therm cytotoxic whereas IFN-gamma and IL-4 render them protective.", MOL. CELL. NEUROSC., vol. 29, March 2005 (2005-03-01), pages 381 - 393, XP004930779 *
CHEN ET AL.: "Glatiramer acetate-reactive T cells produce brain derived neurotrophic factor.", J NEUROL SC., vol. 215, 2003, pages 37 - 44, XP008076627 *
FUKUDA ET AL.: "Stem cells as a source of regenerative cardiomyocytes.", CIRC. RES., vol. 98, April 2006 (2006-04-01), pages 1002 - 1013, XP008107994 *
SILANI ET AL.: "Stem-cell therapy for amyotrophic lateral sclerosis.", LANCET, vol. 364, 2004, pages 200 - 202, XP005070196 *
SIMARD ET AL.: "Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia.", THE FASEB J., vol. 18, April 2004 (2004-04-01), pages 998 - 1000, XP008107995 *
SIMARD ET AL.: "Bone marrow-derived microglia play a critical role in restricting senile plaque formation in alzheimer's disease.", NEURON., vol. 49, February 2006 (2006-02-01), pages 489 - 502, XP002996785 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107988157A (en) * 2017-11-28 2018-05-04 航天中心医院 A kind of Dendritic Cells Induced culture medium and its application
CN107988157B (en) * 2017-11-28 2020-12-15 航天中心医院 A kind of dendritic cell induction medium and its application

Also Published As

Publication number Publication date
WO2008001379A2 (en) 2008-01-03
EP2043666A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
EP2740498A3 (en) Compositions and methods for tissue filling and regeneration
EP2076172A4 (en) Use of coherent raman techniques for medical diagnostic and therapeutic purposes, and calibration techniques for same
WO2009105649A3 (en) Ultrasound guided systems and methods
WO2011066278A3 (en) Methods and systems for chemical ablation
EP2348847A4 (en) Azepino [4, 5-b] indoles and methods of use
EP3251631A3 (en) Tissue expanders
EP2034955A4 (en) Collagen scaffolds, medical implants with same and methods of use
WO2009023256A3 (en) Devices for supporting, elevating, or compressing internal structures
EP2120757A4 (en) THERMOCHEMICAL ABLATION OF BODY TISSUE
ZA200800144B (en) Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
EP2581052A3 (en) Surgical instrument with transducer carrier assembly
WO2007134126A3 (en) After-loader devices and kits and methods for their use
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
MX2015001716A (en) Niclosamide and its derivatives for use in the treatment of solid tumors.
WO2009061800A3 (en) Methods and compositions for diagnostic use in cancer patients
AU2003276665A1 (en) Detecting medical conditions with noninvasive body probes
EP2189101A4 (en) Medical device and device for sampling frozen living tissue
IL200517A (en) Agent for use in the case of fructose intolerance
WO2008042424A3 (en) Thermal strain imaging of tissue
WO2008001379A3 (en) Activated myeloid cells for promoting tissue repair and detecting damaged tissue
ZA200903865B (en) Pyrrole derivatives, preparation and use of the same in therapy
WO2008005942A3 (en) Activatable probes and methods of use
EP2280077A4 (en) Method for detection of cancer cell induced by hpv, method for determination concerning whether or not tissue is in later stage of severe dysplasia, and primer set and kit for use in the methods
ZA200901850B (en) Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof
WO2009133071A3 (en) Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766828

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 196172

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2007766828

Country of ref document: EP